All the news Showing 3 of 53 articles from: Treatment for previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources New hepatitis C drugs danoprevir and mericitabine are safe and effective for prior non-responders and people with cirrhosis Liz Highleyman / 12 November 2012 The experimental hepatitis C drugs danoprevir and mericitabine, with or without pegylated interferon and ribavirin, showed good safety and efficacy in previously treated patients, according to findings from the MATTERHORN study presented at ... Boceprevir a useful option for patients who did not respond to earlier course of hepatitis C therapy Michael Carter / 23 April 2012 A regimen of boceprevir with pegylated interferon and ribavirin achieved cure rates of between 40 and 68% in patients who did not respond to a previous course of hepatitis C therapy, data ... Adding TMC435 boosts response for difficult-to-treat hepatitis C patients Liz Highleyman / 23 April 2012 A combination of TMC435 – also known as simeprevir – plus pegylated interferon and ribavirin raised cure rates for genotype 1 hepatitis C patients who did not respond to previous treatment, according ... ← Prev1...23456Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive